Senior executives at Maverick Capital, one of the well-known ‘Tiger Cub’ hedge funds, say the dominant AI-driven equity rally may be shifting into a more complex and potentially volatile stage, even as they remain constructive on the sector’s long-term prospects, according to a report by Fortune.
Ben Silver and David Tykocinski, co-chief investment officers at the Dallas- and New York-based firm, argue that the rapid buildout of artificial intelligence infrastructure – from chips to data centres – may be approaching a transitional point where returns become less one-directional.
They warn of a possible “air pocket” between heavy investment in AI infrastructure and the broader realisation of productivity gains, a gap they believe could create turbulence across markets heavily exposed to the theme.
The pair lead Maverick Capital, founded by Lee Ainslie, a protégé of legendary investor Julian Robertson. The firm has been a strong performer in recent years, with its flagship fund delivering cumulative gains of more than 70% from early 2021 through mid-2025.
While AI has so far driven outsized returns in areas such as semiconductors, data centre construction and energy infrastructure, the managers say the next phase of value creation may shift as bottlenecks move through the technology stack.
They note that early gains were concentrated in hardware suppliers and infrastructure providers, but argue that the cycle may now evolve as AI becomes more embedded in enterprise systems rather than replacing them outright.
Instead of standalone disruption, they expect greater integration of AI models into existing corporate software and workflows, which could redirect investment focus toward different parts of the technology ecosystem, including enterprise systems, databases and end-user applications.
Alongside their views on AI, the managers are also identifying opportunities in sectors they believe have been overlooked. Silver, who previously led the firm’s healthcare investments, points to life sciences tools companies as a potential beneficiary of renewed pharmaceutical manufacturing investment and AI-driven drug discovery.
They also highlight the possibility of consolidation in that sector, with larger industry players potentially acquiring smaller firms that are currently trading at depressed valuations.
Despite their cautious tone on near-term market dynamics, both executives remain broadly optimistic about AI’s longer-term impact, describing it as a transformative force that will continue to reshape industries over the coming decade.
They emphasise that the evolving cycle requires more selective positioning, as gains may become more dispersed across different parts of the value chain compared with the early stages of the AI boom.
